None listed
Conditions
Brief summary
Preliminary findings suggest aspirin may slow or reduce the rise in core temperature during exercise, improving exercise capacity in individuals with multiple sclerosis (MS). These findings are questionable as the mechanism of action of aspirin does not play any role in active heat production. Cooling interventions like cold water immersion prior to exercise can mitigate heat-related reductions in exercise capacity in individuals with MS. However, many of these interventions are impractical. This project aims to assess the effectiveness of aspirin and skin cooling with a cold water spray on exercise capacity and postural sway in the heat in individuals with MS. It is hypothesised that in individuals with MS, cooling the skin with a cold water spray during exercise, but not ingesting aspirin prior to exercise, will improve exercise capacity and reduce postural sway in the heat.
Interventions
Research Questions The primary research questions guiding this project are: 1) Does oral ingestion of aspirin (650 mg in capsule form) 1 hour prior to exercise improve exercise capacity and reduce postural sway in the heat in a MS population? 2) Does spraying the skin with cold water during exercise improve exercise capacity and reduce postural sway in the heat in a MS population? Research hypotheses: The research hypotheses going into this study are: 1) Oral ingestion of aspirin (650 mg in capsule form) 1 hour prior to exercise will not improve exercise capacity or reduce postural sway in the heat in a MS population. 2) Spraying the skin with cold water during exercise will improve exercise capacity and reduce postural sway in the heat in a MS population. Exercise and balance protocol (assessing exercise capacity and postural sway) The exercise and balance protocol that will be used to test the participants exercise capacity and postural sway in the 3 familiarisation sessions and the 4 experimental trials (separated by at least 10 days for aspirin washout and delivered face-to-face by an Accredited Exercise Physiologist over a total time frame of approx. 2 months) is as follows: 1. 15-minute rest for baseline measures (experimental sessions only) and 15-minute postural sway testing on a low profile pressure-sensing mat 2. 20-minute pre-load cycling on an electronically braked semi-recumbent cycle ergometer at 50% pred. HRR 3. 20 minutes for rest and postural sway testing on a low profile pressure-sensing mat 4. 10-minute cycling time trial on an electronically braked semi-recumbent cycle ergometer 5. 20 minutes for postural sway testing on a low profile pressure-sensing mat and recovery Experimental trials The study will consist of four experimental trials which will take place in the climatic chamber with conditions set at 35ºC/40RH with participants completing the exercise and balance protocol (see details above) with: 1. Control - no intervention 2. Skin cooling using ~11mL of ~18 degree Celsius water sprayed onto the skin of the face, neck and arms every 5 minutes throughout the exercise protocol (COOL) 3. Oral ingestion of 650mg aspirin 1 hour prior to the exercise protocol (ASP) 4. Oral ingestion of one dose of 650mg non-active microcrystalline cellulose 1 hour prior to the exercise protocol (PLA)
Sponsors
Study design
Eligibility
Inclusion criteria
1. Expanded Disability Severity score (EDSS) score between 0 (reflecting no disability or decrement to functional systems) and 5 (reflecting the ability to walk without an aid for 200 meters and mild impairment to functional systems). 2. Between the ages of 18-60 years. 3. Have clinically or laboratory-supported definite MS (clinically diagnosed MS by a neurologist experienced in the treatment of the disease using updated diagnostic criteria). 4. Able to understand the demands of the protocol, has had any questions answered and has voluntarily signed the participant consent form prior to any study procedures. 5. In otherwise good health, based on complete medical history and neurological/physical examination (completed Neurologist/General Practitioner Clearance form). 6. Self-reported sensitivities to the heat.
Exclusion criteria
1. Pregnant subjects (as determined by a urine pregnancy test) 2. Subjects with hypertension, cardiovascular, respiratory, and/or metabolic disorders. 3. Current smokers, as well as individuals who regularly smoked within the past 2 years. 4. Subjects with MS that experienced an exacerbation/relapse (within the past 3 months) 5. On study exacerbation/relapse 6. EDSS >5 7. Seizures 8. Peripheral neuropathy in the legs 9. Arthritis in the legs 10. Mood disorder (e.g. depression, bipolar, psychosis) 11. Allergy to aspirin 12. Peptic ulcer (ulcer in stomach/small intestine) or gastrointestinal bleeding 13. Anaemia (low red blood cell count) 14. Thrombocytopenia (low platelet count) 15. Bleeding diathesis e.g. haemophilia (decreased clotting) 16. Hepatic (liver) disease 17. Renal (kidney) disease 18. Hypothyroidism 19. Stroke 20. Recent major illness 21. Knee or Hip replacement if it causes any issues during exercise 22. Broken bone(s) in the last 5 years if it causes any issues during exercise 23. Any other condition if it causes any self-reported issues during exercise 24. Currently taking Tecfidera 25. Previous Lemtrada infusion 26. Currently has varicella-zoster (chickenpox) virus 27. Currently has Herpes-zoster (shingles) 28. Currently prescribed ongoing non-steroidal anti-inflammatory drug (NSAID) treatment